Similar articles for PMID: 34732455

Year	Number of Results
2014	1
2015	3
2016	4
2017	2
2018	6
2019	17
2020	51
2021	64
2022	58
2023	20
2024	0

1

Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma.

Kato T, Nagahara A, Kawamura N, Nakata W, Soda T, Matsuzaki K, Hatano K, Kawashima A, Ujike T, Imamura R, Nishimura K, Takada S, Tsujihata M, Yamaguchi S, Takao T, Nakai Y, Nakayama M, Nonomura N, Uemura M. Kato T, et al. Anticancer Res. 2021 Nov;41(11):5811-5816. doi: 10.21873/anticanres.15398. Anticancer Res. 2021. PMID: 34732455

2

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L. Auvray M, et al. Eur J Cancer. 2019 Feb;108:33-40. doi: 10.1016/j.ejca.2018.11.031. Epub 2019 Jan 5. Eur J Cancer. 2019. PMID: 30616146

3

Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma.

Bando Y, Furukawa J, Okamura Y, Hara T, Terakawa T, Nakano Y, Fujisawa M. Bando Y, et al. Anticancer Res. 2022 Feb;42(2):973-979. doi: 10.21873/anticanres.15557. Anticancer Res. 2022. PMID: 35093897

4

Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.

Fitzgerald KN, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Aggen DH, Carlo MI, Shah NJ, Voss MH, Feldman DR, Motzer RJ, Lee CH. Fitzgerald KN, et al. Eur Urol. 2023 Mar;83(3):195-199. doi: 10.1016/j.eururo.2022.10.017. Epub 2022 Nov 4. Eur Urol. 2023. PMID: 36344318 Free PMC article.

5

Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.

Pignot G, Thiery-Vuillemin A, Albigès L, Walz J, Lang H, Balssa L, Parier B, Geoffrois L, Bensalah K, Schlürmann F, Ladoire S, Bigot P, Borchiellini D, Cassuto O, Thibault C, Ingels A, Saldana V, Roubaud G, Bernhard JC, Gravis G, Barthélémy P. Pignot G, et al. Eur Urol Oncol. 2022 Oct;5(5):577-584. doi: 10.1016/j.euo.2022.07.002. Epub 2022 Jul 17. Eur Urol Oncol. 2022. PMID: 35853818

6

Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.

Kido K, Hatakeyama S, Numakura K, Tanaka T, Oikawa M, Noro D, Hosogoe S, Narita S, Inoue T, Yoneyama T, Ito H, Nishimura S, Hashimoto Y, Kawaguchi T, Habuchi T, Ohyama C. Kido K, et al. Int J Clin Oncol. 2021 Jan;26(1):154-162. doi: 10.1007/s10147-020-01797-5. Epub 2020 Oct 16. Int J Clin Oncol. 2021. PMID: 33067647

7

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.

Wong JSL, Kwok GGW, Tang V, Li BCW, Leung R, Chiu J, Ma KW, She WH, Tsang J, Lo CM, Cheung TT, Yau T. Wong JSL, et al. J Immunother Cancer. 2021 Feb;9(2):e001945. doi: 10.1136/jitc-2020-001945. J Immunother Cancer. 2021. PMID: 33563773 Free PMC article.

8

Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.

Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT. Laccetti AL, et al. Cancer Med. 2021 Apr;10(7):2341-2349. doi: 10.1002/cam4.3812. Epub 2021 Mar 1. Cancer Med. 2021. PMID: 33650321 Free PMC article.

9

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.

Gul A, Stewart TF, Mantia CM, Shah NJ, Gatof ES, Long Y, Allman KD, Ornstein MC, Hammers HJ, McDermott DF, Atkins MB, Hurwitz M, Rini BI. Gul A, et al. J Clin Oncol. 2020 Sep 20;38(27):3088-3094. doi: 10.1200/JCO.19.03315. Epub 2020 Jun 3. J Clin Oncol. 2020. PMID: 32491962 Free PMC article.

10

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.

Yang Y, Psutka SP, Parikh AB, Li M, Collier K, Miah A, Mori SV, Hinkley M, Tykodi SS, Hall E, Thompson JA, Yin M. Yang Y, et al. Cancer Med. 2022 Aug;11(16):3106-3114. doi: 10.1002/cam4.4679. Epub 2022 Mar 18. Cancer Med. 2022. PMID: 35304832 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

192 results

Results by year